Although increases in cTnI (cardiac troponin I) and cTnT (cardiac troponin T) always indicate myocardial damage, the test is not able to identify the mechanisms responsible for this damage, which may not be due to ischaemia, but rather to other clinical conditions. In the present issue of Clinical Science, Filusch and co-workers have assessed cTnT using a high-sensitive assay in patients with pulmonary arterial hypertension. Their study suggests that, even in patients with extracardiac diseases, high-sensitive troponin assays could lead to better risk stratification of patients in whom conventional cTnT assays show values within the 'normal' range. These findings support the hypothesis that increased levels of cTnI and cTnT are an index of cardiac tissue damage, even in patients with extracardiac diseases, thus enabling appropriate diagnosis and, when necessary and available, specific treatment.
At the dawn of the new century, the discovery of the cardiac-specific biomarkers cTnI (cardiac troponin I) and cTnT (cardiac troponin T) led to the new definition of AMI (acute myocardial infarction) [1, 2] . The application of these international guidelines [1, 2] in clinical practice greatly increased the diagnostic accuracy, leading a 25-55 % increment in diagnosed AMI in the first few years of the century [3] . According to the new definition of AMI [1, 2] , an increase in troponin levels above the 99th URL (99th percentile upper reference limit) should be considered as clinically relevant. Furthermore, it is recommended that the cTnI and cTnT values corresponding to the 99th URL should be measured with an imprecision of 10 % of the coefficient of variation [1, 2] . Unfortunately, none of the immunoassay methods commercially available at the time of the publication of the guidelines were able to fulfil these recommendations [4, 5] .
More recently, a new generation of cTnI and cTnT assays have been set-up by manufacturers in order to improve the analytical performance in accordance with international guidelines [1, 2] and quality specifications [4, 5] . The advent of novel troponin immunoassays with increased analytical sensitivity should actually increase the sensitivity, but also decrease the specificity, in the clinical diagnosis of AMI [4] . Although an increase in cTnI or cTnT always indicates myocardial damage, the test is not able to identify the mechanism responsible for that damage, which may not be due to ischaemia, but to other clinical conditions (Table 1 ) [4] . Indeed, several recent studies have reported troponin values above the 99th URL in many patients without clinical evidence of AMI as 'false-positive' results with decreased assay specificity, especially in the case of advanced age, heart failure, severe co-morbidities, or assuming potential cardiotoxic drugs, as shown in Table 1 [4] . Hence it may not be clear for most patients and physicians whether the new high-sensitive cTnI and cTnT methods will lead to more clarity than confusion [4, 6] . In a paper published in the present issue of Clinical Science, Filusch et al. [7] measured serum cTnT using a conventional assay and a novel hsTnT (high-sensitive cTnT assay) (lower detection limit, 2 pg/ml) in 55 patients (idiopathic, n = 20, chronic thromboembolic, n = 30; and interstitial lung disease, n = 5) with PAH (pulmonary arterial hypertension). The most important results obtained in that study were: (i) cTnT was detectable in 90.9 % of patients using the hsTnT assay, but only in 30.9 % using the conventional method; (ii) cTnT values above the 99th URL were observed in 27.3 % of patients using the hsTnT assay, compared with 10.9 % using the conventional one; (iii) there is a very close correlation between hsTnT and 6MWD (6-min walk distance) (r = −0.92, P = 0.0014); (iv) hsTnT predicted death at least as effectively as hFABP (heart-type fattyacid-binding protein) or NT-proBNP (N-terminal probrain natriuretic peptide); and (v) hsTnT predicted WHO (World Health Organization) class >II better than NTproBNP or hFABP [7] . These results suggest that the novel hsTnT may be useful for risk stratification in patients with PAH. The most important limitation of the study is the relatively low number of patients studied; consequently, the results, in particular those regarding the comparison/association with the other biomarkers (i.e., 6MWD, hFABP and NT-proBNP), should be confirmed in larger clinical studies. PAH is a rare progressive disease that leads to increasing pulmonary vascular resistance, severe right heart failure and premature death [8] . In the U.S.A., the median survival without treatment for the idiopathic form of PAH is only 2.8 years [9] . A recent meta-analysis has shown that only the treatment with intravenous prostacyclins has proven survival benefit in PAH patients, particularly in those with severe disease [9] . However, treatment is not only expensive, but also associated with severe side effects in a relevant proportion of patients. Therefore non-invasive identification of highrisk subgroups may be helpful not only in risk assessment, but also in the selection of treatment modalities and care intensity. Moreover, reliable indicators of clinical worsening and disease severity may be useful to delineate the disease severity and prognosis, as well as to monitor the clinical course and response to therapy [7] . The results reported by Filusch et al. [7] indicate that hsTnT may soon become part of the standard work-up and follow-up of PAH patients.
Any improvement in the analytical precision and clinical sensitivity of a laboratory test is always a good thing; this concept should also be applied to novel generation of hsTnI (high-sensitive cTnI) and hsTnT immunoassays [4] . The high degree of analytical sensitivity (limit of detection <10 pg/ml) and the absolute cardiospecificity of the novel generation of troponin immunoassays allow the detection of very small areas of myocardial damage (probably only 10-50 mg of tissue) [4] .
An increase in analytical and diagnostic sensitivity should allow more accurate and earlier diagnoses. In patients with acute coronary artery syndrome, recent studies have found that elevation of troponin levels can be detected after 2 h (or even earlier) from onset of ischaemic symptoms with the hsTnI and hsTnT immunoassays, but only after 3-6 h with conventional methods [4, 6] . This may lead to earlier triage to an invasive strategy, whereas a repeated normal level at an earlier time point than currently recommended may lead to earlier discharge from the emergency department and cost savings as well [4, 6] . Even in some patients with extracardiac diseases, as suggested by the results reported by Filusch et al. [7] for PAH, high-sensitive troponin assays should enable better risk stratification within the group of patients having values below 99th URL with the conventional assays.
In conclusion, it is really important to stress the concept that increased values of cTnI and cTnT are indexes of cardiac tissue damage, even in patients with extracardiac diseases, such as PAH (or the other clinical conditions listed in Table 1 ), thus suggesting an appropriate diagnosis and, when necessary and available, a specific treatment.
